Enzymatica has appointed Fredrik Lindberg as CEO, to take up his position in spring 2015. He will succeed Christian W Jansson, who has served as acting CEO since September 2014.
Fredrik Lindberg is the Chief Scientific Officer and co-founder of Bone Support AB, and its CEO during the period 2001-2012. He has been a member of the Board of Enzymatica since 2012 and has good insight into the company.
"Enzymatica is in a phase of expansion where the combination of international sales and product development is essential. With his previous experience and knowledge of Enzymatica Fredrik will be able to take the company towards the next phase of its development right from the start, which means further expansion and development of the business", says Christian W Jansson, acting CEO of Enzymatica.
Fredrik Lindberg has extensive experience from the life science industry and from growth companies with international operations. Previous positions include CEO of Bone Support AB, Nordic Medical Director of Searle Pharmaceuticals, and Head of the Department of Clinical Pharmacology at the University Hospital in Lund. He is an MD, PhD and an Associate Professor of Clinical Pharmacology.
"I am delighted to have the opportunity to become actively involved in the development of Enzymatica. I have followed Enzymatica’s progress closely for some years and am fascinated by the potential of the company’s enzyme technology and the expertise in the organization. Having the opportunity to lead the work in such an environment is both an honor and an inspiring challenge", says Fredrik Lindberg.
When he takes over as CEO of Enzymatica Fredrik Lindberg will resign from the Board. Christian W Jansson will return as Chairman.
A photo of Fredrik Lindberg is attached (Photo: Enzymatica AB).
For more information, please contact:
Christian W Jansson, acting CEO Enzymatica AB
Phone: +46 706-37 12 58. E-mail: firstname.lastname@example.org
Tina Dackemark Lawesson, Senior Communications Officer Enzymatica AB
Phone: +46 46 286 31 00. Email: email@example.com
About Enzymatica AB (publ)
Enzymatica AB (publ) develops and sells medical technology products based on an enzyme from deep-sea cod. Our development includes medical devices in upper respiratory infections and oral health, and veterinary products in oral health and dermatology. The launched medical portfolio includes ColdZyme® against common colds. The company is headquartered in Lund, Sweden, and is listed on Aktietorget. For more information, please visit www.enzymatica.com.